Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Three for three
March 2016
EDIT CONNECT

SHARING OPTIONS:

TEL AVIV, Israel—Compugen Ltd. recently reached the third preclinical milestone in its collaboration with Bayer HealthCare, which is centered on the research, development and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022. This milestone relates to CGEN-15001T and, with its achievement, the program has now been transferred to Bayer’s full control for further preclinical and clinical development activities and worldwide commercialization, under milestone and royalty bearing licenses from Compugen. CGEN-15022 will continue under the joint preclinical research program. Compugen and Bayer began their collaboration and license agreement in August 2013, and Compugen stands to receive more than $500 million in milestone payments for both programs, as well as $30 million in milestones associated with joint preclinical research.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.